Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.67 Analyst target: $61.25 Upside: 3567.66%
Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions. The company is headquartered in Miami, Florida.
See the full interactive analysis & chart →Informational only — not investment advice.